<DOC>
	<DOCNO>NCT01794091</DOCNO>
	<brief_summary>People diabetes increase risk heart attack heart failure , important able treat people diabetes risk heart disease prevent outcomes . This study look importance `` diffuse scar tissue '' find heart diabetic people . We discover way detect diffuse scar tissue cardiac MRI , non-invasive test . In study , cardiac MRI diabetic low risk stress test result follow 5 year see measure scar tissue heart MRI relate event . If study positive , able use cardiac MRI scar tissue measurement target patient diabetes high risk .</brief_summary>
	<brief_title>Detection Diffuse Scar Patients With Diabetes</brief_title>
	<detailed_description>This study conduct TWO ( 2 ) PHASES : Phase 1 : Prospective cohort study patient diabetes mellitus , index cardiac MRI do screen determine FIBROTIC INDEX . Patients subsequently follow 5 year primary endpoint ( composite cardiovascular event ) . Phase 2 : Of patient `` HIGH '' FIBROTIC INDEX , 50 patient randomly select randomize 1:1 placebo : eplerenone 25 mg daily 6 month , repeat cardiac MRI do assess fibrotic index post-treatment . Phase 2 PILOT study 50 patient . The inclusion/exclusion criterion different phase show .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>For PHASE I ( Prospective Cohort Study determine prognostic value fibrotic index ) Diabetes mellitus , type II Age &gt; = 40 year UKPDS 10 year Risk Score &gt; 15 % Low risk stress test ( define explicitily protocol ) suspect confirmed myocarditis infiltrative disease ( include hemochromatosis , sarcoid , amyloid ) history prior MI coronary revascularization ( Q wave electrocardiogram 2 contiguous lead clinical history ) clinical HF ( prior hospital admission HF documentation reduce LV ejection fraction index CMR ) metallic hazard hematocrit &lt; 30 % ( within 1 year nuclear stress test ) history active bleeding ( within 3 month stress test ) estimate GFR ( Modified Diet Renal Disease ) &lt; 45 ml/min/1.73m2 ( within 2 week plan CMR ) pregnancy severe noncardiac illness prognosis ( e.g. , end stage liver disease , malignancy , advanced HIV/AIDS ) For PHASE 2 : Included Phase I Systolic blood pressure &gt; 140 mmHg two occasion ( initial nuclear stress test index cardiac MRI ) Exclusion criterion : 1 . Concomitant cytochrome P450 ( CYP3A4 ) inhibitors inducer ; 2 . Concomitant potassium supplementation potassium spar diuretic ; 3 . Concomitant use ACE inhibitor ARB therapy ( dose ) ; 4 . Renal dysfunction ( GFR &lt; 50 ml/min serum creatinine &gt; 1.5 mg/dL ( assessed time index CMR ) ; 5 . Any urine microalbuminuria ( assessed time index CMR ) ; 6 . Baseline ( pretherapy ) serum potassium &gt; 5.0 mEq/L ; 7 . Lack reliable telephone contact number relay result need discontinue drug therapy ; 8 . Age &gt; 75 year ( give tendency toward renal insufficiency capture GFR , dehydration and/or concomitant illness ) 9 . Women able become pregnant ( give undefined risk eplerenone therapy pregnant woman newborn ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Cardiac Magnetic Resonance Imaging</keyword>
	<keyword>Diabetes</keyword>
</DOC>